Related Experiment Video

Updated: May 30, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

New developments in mammalian target of rapamycin inhibitors for the treatment of sarcoma

Mark Agulnik1

  • 1Division of Medical Hematology/Oncology, Northwestern University, Chicago, Illinois, USA. m-agulnik@northwestern.edu

Cancer
|August 13, 2011
PubMed

Insights

Targeting the mammalian target of rapamycin (mTOR) pathway with rapalogs shows promise for treating advanced sarcomas. Further research is recommended for these mTOR inhibitors in sarcoma therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Sarcomas are rare cancers with limited treatment options, especially in advanced stages.
  • The mammalian target of rapamycin (mTOR) signaling pathway regulates critical cellular processes like proliferation and metabolism.
  • Aberrations in the mTOR pathway are frequently observed in various sarcoma subtypes, highlighting its therapeutic potential.

Purpose of the Study:

  • To evaluate the potential of targeting the mTOR signaling pathway for sarcoma treatment.
  • To review the efficacy of rapamycin and its analogs (rapalogs) in preclinical and clinical studies for sarcomas.

Main Methods:

  • Review of preclinical models investigating mTOR-targeting agents.
  • Analysis of clinical trial data for rapalogs in sarcoma patients, both as monotherapy and in combination regimens.

Main Results:

  • Rapalogs demonstrated significant anticancer activity in preclinical sarcoma models.
  • Clinical trials indicated potential benefits of rapalogs, alone or with other therapies, in treating several sarcoma types.

Conclusions:

  • The mTOR pathway is a viable therapeutic target for various sarcomas.
  • Rapalogs show promise and warrant further investigation for advanced sarcoma treatment.

More Related Videos

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model13:41

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Published on: January 13, 2023

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...